Black Amanda, Huang Wen-Yi, Wright Patrick, Riley Tom, Mabie Jerome, Mathew Sunitha, Ragard Lawrence, Hermansen Sigurd, Yu Kelly, Pinsky Paul, Prorok Philip C, Freedman Neal D, Hoover Robert N
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, USA.
Rev Recent Clin Trials. 2015;10(3):238-45. doi: 10.2174/157488711003150928130654.
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a large-scale, multi-institutional, randomized controlled trial, was launched in 1992 to evaluate the effectiveness of screening modalities for prostate, lung, colorectal, and ovarian cancer. However, PLCO was additionally designed to serve as an epidemiologic resource and the National Cancer Institute has invested substantial resources over the years to accomplish this goal. In this report, we provide a summary of changes to PLCO's follow-up after conclusion of the screening phase of the trial and highlight recent data and biospecimen collections, including ancillary studies, geocoding, administration of a new medication use questionnaire, consent for linkage to Medicare, and additional tissue collection that enhance the richness of the PLCO resource and provide further opportunities for scientific investigation into the prevention, early detection, etiology and treatment of cancer.
前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）是一项大规模、多机构的随机对照试验，于1992年启动，旨在评估前列腺癌、肺癌、结直肠癌和卵巢癌筛查方式的有效性。然而，PLCO还被设计用作一种流行病学资源，多年来美国国立癌症研究所投入了大量资源来实现这一目标。在本报告中，我们总结了PLCO试验筛查阶段结束后随访情况的变化，并重点介绍了近期的数据和生物样本采集情况，包括辅助研究、地理编码、一份新的用药问卷的管理、与医疗保险关联的同意书以及额外的组织采集，这些都增强了PLCO资源的丰富性，并为癌症预防、早期检测、病因学和治疗的科学研究提供了更多机会。
